<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2273">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04720001</url>
  </required_header>
  <id_info>
    <org_study_id>STU00206530</org_study_id>
    <nct_id>NCT04720001</nct_id>
  </id_info>
  <brief_title>Florbetaben PET Imaging in PPA</brief_title>
  <official_title>Florbetaben PET Imaging in Primary Progressive Aphasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to better understand how dementia affects activity in&#xD;
      different parts of the brain.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will examine Positron Emission Tomography (PET) imaging with Florbetaben F18.&#xD;
      Florbetaben F18 is a radioactive tracer that binds to particles in your brain. This process&#xD;
      displays activity in the brain. Florbetaben F18 is a PET amyloid imaging agent approved by&#xD;
      the United States Food and Drug Administration (FDA) to estimate the amount of beta-amyloid&#xD;
      plaque in adult patients who are being evaluated for Alzheimer's disease and other causes of&#xD;
      cognitive decline. The purpose of this research is to better understand how dementia affects&#xD;
      activity in different parts of the brain. Currently, the scientific community is limited by&#xD;
      how well it can see inside the brain. The use of a PET scan better helps us understand what&#xD;
      the brain looks like in a diseased state. Participation in the study will help to understand&#xD;
      what brain activity looks like, especially around language regions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 23, 2018</start_date>
  <completion_date type="Actual">February 26, 2021</completion_date>
  <primary_completion_date type="Actual">January 21, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Amyloid plaque levels in PPA participants</measure>
    <time_frame>2 Years</time_frame>
    <description>Amyloid plaque aggregation as measured by florbetaben F18 standard uptake value ratio cerebral and cerebellar regions of interest.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1</enrollment>
  <condition>Primary Progressive Aphasia</condition>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Experimental: Florbetaben F18 recipients</arm_group_label>
    <description>Participants in this arm of the study will receive 8.1mCi of florbetaben F18 and then be scanned in a PET scanner for brain imaging.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Florbetaben F18</intervention_name>
    <description>A single injection of 8.1mCi of florbetaben F18 will be administered by intravenous bolus injection</description>
    <arm_group_label>Experimental: Florbetaben F18 recipients</arm_group_label>
    <other_name>trade name NeuraCeq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PET</intervention_name>
    <description>PET Scan for brain imaging</description>
    <arm_group_label>Experimental: Florbetaben F18 recipients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants will be recruited from other research projects at Northwestern's Mesulam&#xD;
        Center. Some of these projects recruit participants from the local Chicagoland area and&#xD;
        others recruit participants from across the United States. As Primary Progressive Aphasia&#xD;
        is an uncommon syndrome, participant recruitment is not focused on a specific demographic&#xD;
        area.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must have a diagnosis of PPA or a related dementia syndrome&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  Breastfeeding&#xD;
&#xD;
          -  Receiving radiation clinically&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emily Rogalski, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cognitive Neurology and Alzheimer's Disease Center - Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2022</verification_date>
  <study_first_submitted>January 19, 2021</study_first_submitted>
  <study_first_submitted_qc>January 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>February 21, 2022</last_update_submitted>
  <last_update_submitted_qc>February 21, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Emily Rogalski</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>Dementia</keyword>
  <keyword>Primary Progressive Aphasia</keyword>
  <keyword>Neurocognitive Disorders</keyword>
  <keyword>Speech Disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Aphasia</mesh_term>
    <mesh_term>Aphasia, Primary Progressive</mesh_term>
    <mesh_term>Pick Disease of the Brain</mesh_term>
    <mesh_term>Frontotemporal Dementia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

